Michael V Cohen

List of Publications by Year
in descending order

42 papers	3,502 citations	186265 28 h-index	289244 40 g-index
42 all docs	42 docs citations	42 times ranked	2803 citing authors

#	Article	IF	Citations
1	Multiple, brief coronary occlusions during early reperfusion protect rabbit hearts by targeting cell signaling pathways. Journal of the American College of Cardiology, 2004, 44, 1103-1110.	2.8	459
2	Ischemic Preconditioning: From Adenosine Receptor to KATPChannel. Annual Review of Physiology, 2000, 62, 79-109.	13.1	454
3	Acetylcholine, Bradykinin, Opioids, and Phenylephrine, but not Adenosine, Trigger Preconditioning by Generating Free Radicals and Opening Mitochondrial K ATP Channels. Circulation Research, 2001, 89, 273-278.	4.5	285
4	The pH Hypothesis of Postconditioning. Circulation, 2007, 115, 1895-1903.	1.6	267
5	Adenosine: trigger and mediator of cardioprotection. Basic Research in Cardiology, 2008, 103, 203-215.	5.9	186
6	Platelet P2Y₁₂ Blockers Confer Direct Postconditioning-Like Protection in Reperfused Rabbit Hearts. Journal of Cardiovascular Pharmacology and Therapeutics, 2013, 18, 251-262.	2.0	133
7	Caspase-1 inhibition by VX-765 administered at reperfusion in P2Y12 receptor antagonist-treated rats provides long-term reduction in myocardial infarct size and preservation of ventricular function. Basic Research in Cardiology, 2018, 113, 32.	5.9	127
8	Title is missing!. Molecular and Cellular Biochemistry, 1998, 186, 3-12.	3.1	125
9	Nitric oxide is a preconditioning mimetic and cardioprotectant and is the basis of many available infarct-sparing strategies. Cardiovascular Research, 2006, 70, 231-239.	3.8	111
10	Signal Transduction in Ischemic Preconditioning:.. Journal of Cardiovascular Electrophysiology, 1999, 10, 741-754.	1.7	110
11	Acidosis, oxygen, and interference with mitochondrial permeability transition pore formation in the early minutes of reperfusion are critical to postconditioningâ€™s success. Basic Research in Cardiology, 2008, 103, 464-471.	5.9	106
12	Circulating blood cells and extracellular vesicles in acute cardioprotection. Cardiovascular Research, 2019, 115, 1156-1166.	3.8	106
13	Signalling pathways and mechanisms of protection in preâ€•and postconditioning: historical perspective and lessons for the future. British Journal of Pharmacology, 2015, 172, 1913-1932.	5.4	100
14	Ischemic preconditioning depends on interaction between mitochondrial K_{ATP}channels and actin cytoskeleton. American Journal of Physiology - Heart and Circulatory Physiology, 1999, 276, H1361-H1368.	3.2	97
15	Ischemic Postconditioning: From Receptor to End-Effector. Antioxidants and Redox Signaling, 2011, 14, 821-831.	5.4	87
16	Triple Therapy Greatly Increases Myocardial Salvage During Ischemia/Reperfusion in the in situ Rat Heart. Cardiovascular Drugs and Therapy, 2013, 27, 403-412.	2.6	74
17	Chelerythrine, a highly selective protein kinase C inhibitor, blocks the antiinfarct effect of ischemic preconditioning in rabbit hearts. Cardiovascular Drugs and Therapy, 1994, 8, 881-882.	2.6	67
18	MYOCARDIAL PRECONDITIONING PROMISES TO BE A NOVEL APPROACH TO THE TREATMENT OF ISCHEMIC HEART DISEASE. Annual Review of Medicine, 1996, 47, 21-29.	12.2	65

#	Article	IF	Citations
19	Preconditioning-mimetics bradykinin and DADLE activate PI3-kinase through divergent pathways. Journal of Molecular and Cellular Cardiology, 2007, 42, 842-851.	1.9	62
20	Two Classes of Anti-Platelet Drugs Reduce Anatomical Infarct Size in Monkey Hearts. Cardiovascular Drugs and Therapy, 2013, 27, 109-115.	2.6	61
21	SB 203580, an inhibitor of p38 MAPK, abolishes infarct-limiting effect of ischemic preconditioning in isolated rabbit hearts. Basic Research in Cardiology, 2000, 95, 466-471.	5.9	56
22	Mitochondrially targeted Endonuclease III has a powerful anti-infarct effect in an in vivo rat model of myocardial ischemia/reperfusion. Basic Research in Cardiology, 2015, 110, 3.	5.9	55
23	Cangrelor-Mediated Cardioprotection Requires Platelets and Sphingosine Phosphorylation. Cardiovascular Drugs and Therapy, 2016, 30, 229-232.	2.6	43
24	The impact of irreproducibility and competing protection from P2Y12 antagonists on the discovery of cardioprotective interventions. Basic Research in Cardiology, 2017, 112, 64.	5.9	42
25	The Highly Selective Caspase-1 Inhibitor VX-765 Provides Additive Protection Against Myocardial Infarction in Rat Hearts When Combined With a Platelet Inhibitor. Journal of Cardiovascular Pharmacology and Therapeutics, 2017, 22, 574-578.	2.0	41
26	Smaller infarct after preconditioning does not predict extent of early functional improvement of reperfused heart. American Journal of Physiology - Heart and Circulatory Physiology, 1999, 277, H1754-H1761.	3.2	38
27	Do mitochondrial K ATP channels serve as triggers rather than end-effectors of ischemic preconditioning's protection?. Basic Research in Cardiology, 2000, 95, 272-274.	5.9	28
28	Is It Time to Translate Ischemic Preconditioningâ€™s Mechanism of Cardioprotection into Clinical Practice?. Journal of Cardiovascular Pharmacology and Therapeutics, 2011, 16, 273-280.	2.0	28
29	The Role of Pyroptosis in Ischemic and Reperfusion Injury of the Heart. Journal of Cardiovascular Pharmacology and Therapeutics, 2021, 26, 562-574.	2.0	20
30	A deep-learning semantic segmentation approach to fully automated MRI-based left-ventricular deformation analysis in cardiotoxicity. Magnetic Resonance Imaging, 2021, 78, 127-139.	1.8	13
31	Introduction to a mechanism for automated myocardium boundary detection with displacement encoding with stimulated echoes (DENSE). British Journal of Radiology, 2018, 91, 20170841.	2.2	10
32	Ticagrelor Does Not Protect Isolated Rat Hearts, Thus Clouding Its Proposed Cardioprotective Role Through ENT 1 in Heart Tissue. Journal of Cardiovascular Pharmacology and Therapeutics, 2019, 24, 371-376.	2.0	9
33	Biventricular diastolic dysfunction, thrombocytopenia, and red blood cell macrocytosis in experimental pulmonary arterial hypertension. Pulmonary Circulation, 2020, 10, 1-12.	1.7	7
34	Ischemic Preconditioning Through Opening of Swelling-Activated Chloride Channels?. Circulation Research, 2001, 89, .	4.5	6
35	What Are Optimal P2Y12 Inhibitor and Schedule of Administration in Patients With Acute Coronary Syndrome?. Journal of Cardiovascular Pharmacology and Therapeutics, 2020, 25, 121-130.	2.0	6
36	Can post-chemotherapy cardiotoxicity be detected in long-term survivors of breast cancer via comprehensive 3D left-ventricular contractility (strain) analysis?. Magnetic Resonance Imaging, 2019, 62, 94-103.	1.8	5

#	Article	IF	Citations
37	Efficacy of preconditioning should be gauged by reduction of infarction. British Journal of Pharmacology, 2004, 141, 197-198.	5.4	4
38	Direct left-ventricular global longitudinal strain (GLS) computation with a fully convolutional network. Journal of Biomechanics, 2022, 130, 110878.	2.1	4
39	Letter by Downey and Cohen Regarding Article, â€œProtective Effects of Ticagrelor on Myocardial Injury After Infarctionâ€• Circulation, 2017, 135, e1000-e1001.	1.6	3
40	Validation of a deep-learning semantic segmentation approach to fully automate MRI-based left-ventricular deformation analysis in cardiotoxicity. British Journal of Radiology, 2021, 94, 20201101.	2.2	2
41	A2B or not 2B: that is the question: AUTHORS' RETROSPECTIVE. Cardiovascular Research, 2012, 96, 198-201.	3.8	0
42	Myocardial Stunning After Electrocution With Complete Reversibility Within 24 Hours: Role of Repeat Transthoracic Echocardiograms in Potential Cardiac Transplant Donors. Cardiology Research, 2018, 9, 268-272.	1.1	0